Vallon Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $5.02 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vallon Pharmaceuticals Inc had its IPO on 2021-02-10 under the ticker symbol VLON.
The company operates in the Healthcare sector and Biotechnology industry. Vallon Pharmaceuticals Inc has a staff strength of 2 employees.
Shares of Vallon Pharmaceuticals Inc opened at $0.38 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $0.35 - $0.39, and closed at $0.36.
This is a -2.8% slip from the previous day's closing price.
A total volume of 227,822 shares were traded at the close of the day’s session.
In the last one week, shares of Vallon Pharmaceuticals Inc have slipped by -11.8%.
Vallon Pharmaceuticals Inc's Key Ratios
Vallon Pharmaceuticals Inc has a market cap of $5.02 million, indicating a price to book ratio of 0.8381 and a price to sales ratio of 247.2775.
In the last 12-months Vallon Pharmaceuticals Inc’s revenue was $0 with a gross profit of $100000 and an EBITDA of $-6722000. The EBITDA ratio measures Vallon Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vallon Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -69.35% with a return of equity of -172.16%.
In Q4, Vallon Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Vallon Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.65 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vallon Pharmaceuticals Inc’s profitability.
Vallon Pharmaceuticals Inc stock is trading at a EV to sales ratio of 251.5571 and a EV to EBITDA ratio of 0.5263. Its price to sales ratio in the trailing 12-months stood at 247.2775.
Vallon Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $4.15 million
- Total Liabilities
- $1.81 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Vallon Pharmaceuticals Inc ended 2023 with $4.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $4.15 million while shareholder equity stood at $2.34 million.
Vallon Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $1.81 million in other current liabilities, 1000.00 in common stock, $-28926000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.78 million and cash and short-term investments were $3.78 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Vallon Pharmaceuticals Inc’s total current assets stands at $4.15 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $977000.00 and inventory worth $0.
In 2023, Vallon Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Vallon Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vallon Pharmaceuticals Inc stock is currently trading at $0.36 per share. It touched a 52-week high of $2.68 and a 52-week low of $2.68. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.43 and 200-day moving average was $0.39 The short ratio stood at 0.05 indicating a short percent outstanding of 0%.
Around 2341.7% of the company’s stock are held by insiders while 1328.3% are held by institutions.
Frequently Asked Questions About Vallon Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company’s lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.